Assessment of possible adulteration of a urine specimen submitted for drug of abuse testing
Providing the creatinine concentration for normalization purposes
See Adulterant Survey Algorithm in Special Instructions
Spectrophotometry (SP)
See Adulterant Survey Algorithm in Special Instructions
Urine
Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 1.5 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Additional Information:
1. For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody information, see ADLTX / Adulterants Survey, Chain of Custody, Random, Urine.
2. Submitting less than 1.5 mL may compromise the ability to perform all necessary testing.
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
1 mL
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 14 days | |
Frozen | 14 days | ||
Ambient | 72 hours |
Assessment of possible adulteration of a urine specimen submitted for drug of abuse testing
Providing the creatinine concentration for normalization purposes
See Adulterant Survey Algorithm in Special Instructions
Specimen adulteration is the manipulation of a sample that may cause falsely negative test results for the presence of drugs of abuse. Common adulterants that may affect testing are water, soap, bleach, vinegar, oxidants, and salt. The adulteration testing includes assessment of creatinine concentration, pH, urine specific gravity, presence or absence of an oxidant, and presence or absence of nitrite.
Cutoff concentrations
Oxidants: 200 mg/L
Nitrites: 500 mg/L
See Adulterant Survey Algorithm in Special Instructions.
No significant cautionary statements
1. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA): Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register. 2017 January 23;82(13):FR 7920. Available at: www.samhsa.gov/sites/default/files/workplace/frn_vol_82_7920_.pdf
2. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA): Drug-Free Workplace Guidelines and Resources Updated June 7, 2021. Accessed September 27, 2021. Available at: www.samhsa.gov/workplace/resources
All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement.(Package inserts: Creatinine plus ver 2, Specimen Validity Test Nitrite, Specimen Validity Test Oxidant, Specimen Validity Test pH, Specimen Validity Test Specific Gravity. Roche Diagnostics; 12/2016)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
81005
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
ADULT | Adulterants Survey, U | 58714-7 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
20606 | Creatinine, U | 2161-8 |
22312 | Specific Gravity | 5810-7 |
23509 | pH | 2756-5 |
23511 | Oxidants | 58714-7 |
23510 | Nitrites | 32710-6 |
30914 | Comment | 48767-8 |
Change Type | Effective Date |
---|---|
Test Changes - Specimen Information | 2021-10-25 |